![Kyle Jenne](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Kyle Jenne
Corporate Officer/Principal bij IONIS PHARMACEUTICALS, INC.
Vermogen: 74 727 $ op 31-05-2024
Profiel
Kyle Jenne is currently the Executive Vice President-Commercial at Ionis Pharmaceuticals, Inc. He previously held positions as the Chief Executive Officer & Director at Elsie Biotechnologies Inc., the Chief Commercial Officer & Executive VP at Ionis Pharmaceuticals, Inc., and the Senior Vice President-US Commercial at Akcea Therapeutics, Inc. Mr. Jenne completed his undergraduate degree at Arizona State University.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
26-02-2024 | 1 989 ( 0.00% ) | 74 727 $ | 31-05-2024 |
Actieve functies van Kyle Jenne
Bedrijven | Functie | Begin |
---|---|---|
IONIS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 29-02-2024 |
Eerdere bekende functies van Kyle Jenne
Bedrijven | Functie | Einde |
---|---|---|
IONIS PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Elsie Biotechnologies Inc.
![]() Elsie Biotechnologies Inc. BiotechnologyHealth Technology Part of GSK Plc, Elsie Biotechnologies Inc. is a private biopharmaceutical company dedicated to unlocking the full potential of oligonucleotide therapeutics. The company is based in San Diego, CA. Elsie Biotechnologies integrates discovery, development, and delivery to increase potency, decrease toxicity, and optimize delivery of oligonucleotide therapeutics. The company's platform accesses the entire oligonucleotide chemistry space to optimize gene silencing and splice switching, and develops novel oligonucleotide therapeutics that are more potent, safer, and easier to deliver to target tissues. Elsie Biotechnologies is focused on unlocking the full potential of RNA therapeutics to treat undruggable diseases. The company was founded in 2021 by Phil Baran and Philip E. Dawson. The CEO is Kevin Green. Elsie Biotechnologies was acquired by GSK Plc on June 06, 2024 for $50 million. | Algemeen Directeur | - |
AKCEA THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Opleiding van Kyle Jenne
Arizona State University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
IONIS PHARMACEUTICALS, INC. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Akcea Therapeutics, Inc.
![]() Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
Elsie Biotechnologies Inc.
![]() Elsie Biotechnologies Inc. BiotechnologyHealth Technology Part of GSK Plc, Elsie Biotechnologies Inc. is a private biopharmaceutical company dedicated to unlocking the full potential of oligonucleotide therapeutics. The company is based in San Diego, CA. Elsie Biotechnologies integrates discovery, development, and delivery to increase potency, decrease toxicity, and optimize delivery of oligonucleotide therapeutics. The company's platform accesses the entire oligonucleotide chemistry space to optimize gene silencing and splice switching, and develops novel oligonucleotide therapeutics that are more potent, safer, and easier to deliver to target tissues. Elsie Biotechnologies is focused on unlocking the full potential of RNA therapeutics to treat undruggable diseases. The company was founded in 2021 by Phil Baran and Philip E. Dawson. The CEO is Kevin Green. Elsie Biotechnologies was acquired by GSK Plc on June 06, 2024 for $50 million. | Health Technology |